Tags : Sartorius

Insights+ COVID-19 Deals (Part II): Biopharma Vaccine Development

The recent emergence of the coronavirus SARS-CoV-2 and the COVID-19 pandemic has spurred global healthcare and life sciences companies, as well as government agencies, to partner at unprecedented speed to develop vaccines, treatments, and tests.  This article covers the last four months of deal data provided by Chris Dokomajilar of DealForma. During the last four months […]Read More

PharmaShots’ Key Highlights of Fourth Quarter 2019

1. Pfizer Launched its Zirabev (biosimilar, bevacizumab) in the US by the year end 2019 Date – Oct 01, 2019 Product – Zirabev (biosimilar, bevacizumab) The biosimilar was launched in the US on Dec 31, 2019 following the settlement between Genentech and Pfizer granting all global rights of the product to the Pfizer. In Sept […]Read More

PharmaShots Weekly Snapshot (October 21-25, 2019)

1. Urology San Antonio Collaborates with Anixa Biosciences on Ccheck Prostate Cancer Study Published: Oct 25, 2019 | Tags: Urology San Antonio, Collaborates, Anixa Biosciences, Ccheck, Prostate Cancer Study 2. NHS England Signs an Agreement with Vertex to Access All Licensed Cystic Fibrosis Therapies Published: Oct 24, 2019 | Tags: NHS England, Signs, Agreement, Vertex, Access, Licensed, […]Read More

Sartorius to Acquire Danaher’s Life Science Portfolio for $750M

Shots: The life science portfolio to be acquired includes label-free biomolecular characterization (FortéBio), chromatography hardware and resins, and microcarriers (SoloHill) businesses. The proposed transaction follows Danaher’s GE Biopharma business and related regulatory approval The transaction is expected to be completed in Q1’20 and will strengthen Sartorius’ presence in bioanalytics and bioprocessing segments with the acquisition […]Read More